Ku ya 22 Mutarama 2025, "Nature Medicine" yasohoye ibyavuye muri Akeso ku giti cyayo yakoze cadonilimab ya PD-1/CTLA-4 bispecific antibody hamwe na oxaliplatin na capecitabine mu rwego rwo kuvura indwara ya G/GEJ (G/GEJ) adenocarcinoma idakira cyangwa ikwirakwira mu gace runaka mu bushakashatsi bwakozwe ku cyiciro cya gatatu (COMPASSION-15/AK104-302).Ibyavuye mu bushakashatsi bwa COMPASSION-15 byatanzwe mbere mu magambo mu nama ngarukamwaka y’ishyirahamwe ry’Abanyamerika rishinzwe ubushakashatsi ku ndwara ya kanseri (AACR) yo mu 2024.
Ubu bushakashatsi bwari ubwakozwe ku buryo butunguranye, budafite ubumuga bwo kuvura, kandi bugenzurwa n’itsinda rya 3 rya placebo. Abarwayi bujuje ibisabwa bari abantu bakuru bafite adenocarcinoma ya G/GEJ idakira, idakira, yateye imbere mu gace runaka cyangwa yanduye. Abarwayi bakorewe ku buryo butunguranye 1:1 kugira ngo bahabwe cadonilimab (10 mg−1 buri byumweru 3) cyangwa placebo hamwe na chemotherapy (buri byumweru 3). Ishingiro ry’ibanze ryari ubuzima rusange (OS) mu bantu bari biteguye kuvura (urwego rw’uburemere bw’uruhande rumwe, P = 0.025). Ishingiro ry’inshuro ebyiri ryarimo OS mu barwayi bafite amanota 65 ya PD-L1, kubaho nta guhindagurika kw’imiti, igipimo cyo gusubiza neza, igihe cyo gusubiza n’umutekano. Kugeza ku ya 18 Kanama 2023, abarwayi 610 bo mu bigo 75 by’ubushakashatsi bakorewe cadonilimab ku buryo butunguranye (n = 305) cyangwa placebo (n = 305). Hamwe n'ikurikirana ry'amezi 18.7, itsinda rya cadonilimab ryari rifite ikigereranyo cy'imikorere y'umubiri (14.1 ugereranyije n'amezi 11.1; igipimo cy'ibyago (HR) 0.66; 95% igihe cy'icyizere (CI) 0.54–0.81; P < 0.001) ugereranyije n'itsinda rya placebo. Iherezo ry'ibanze ryagezweho. Igipimo cy'imibereho y'abarwayi bafite PD-L1 nta ngaruka mbi yatewe cyari amezi 7.0 ugereranyije n'amezi 5.3 (HR 0.53, 95% CI 0.44–0.65). Igipimo cy'imikorere y'umubiri ku barwayi bafite PD-L1 cyahuje amanota ≥5 cyari amezi 15.3 ugereranyije n'amezi 10.9 (HR 0.58, 95% CI 0.41–0.82). Igipimo cy'inyishu cyari 65.2% ugereranyije na 48.9%, igihe cy'inyishu cyari amezi 8.8 ugereranyije n'amezi 4.4. Ibyago bibi bikomoka ku buvuzi byagaragaye ku rwego rwa ≥3 byagaragaye kuri 65.9% by'itsinda rya cadonilimab na 53.6% by'itsinda rya placebo, kandi ibikunze kugaragara ni ukugabanuka kw'umubare wa platelet, kugabanuka kw'umubare wa neutrophil na anemia. Ibyinshi mu byago bibi bikomoka ku budahangarwa bw'umubiri byari mu rwego rwa 1 cyangwa 2. Nta bimenyetso bishya by'umutekano byagaragaye. Cadonilimab hamwe na chimiotherapie byazamuye cyane OS hamwe n'umutekano ugenzurwa ku barwayi bafite G/GEJ adenocarcinoma iteye imbere.
Guterwa Cadonilimab ni umuti mushya, wa mbere mu bwoko bwa PD-1/CTLA-4 wihariye mu buvuzi bw’umubiri wakozwe mu kigo. Ku ya 29 Kamena 2022, Cadonilimab yemerewe na NMPA yo mu Bushinwa kuvura kanseri y’inkondo y’umura yasubiwemo cyangwa yahindutse (R/M CC) yakomeretse nyuma ya kanseri ya platine cyangwa nyuma yayo. Muri Nzeri 2024, ikimenyetso gishya cya cadonilimab cyemejwe mu kuvura abarwayi bafite adenocarcinoma idakira cyangwa yahindutse mu gifu cyangwa mu gifu (G/GEJ) adenocarcinoma, hamwe na fluoropyrimidine na platine. Ubu, imiti mishya ya Cadonilimab ivanze na platine-based chemotherapy, hamwe na bevacizumab cyangwa idafite, mu kuvura kanseri y’inkondo y’umura ihoraho, isubiramo, cyangwa yahindutse, yemejwe na CDE. Byongeye kandi, hari ubushakashatsi butandukanye bwo kwa muganga, harimo n’igerageza ry’icyiciro cya gatatu ku barwayi bafite ibyago byinshi byo kongera kugaruka nyuma yo gucibwa kanseri y’umwijima, buri gukorwa neza.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Email：myimmnet@163.com
Amareferensi
https://www.nature.com/articles/s41591-024-03450-4
Igihe cyo kohereza: Gashyantare-21-2025